

January 31, 2025

To, To,

**BSE Limited**, The Manager, 25, P. J. Towers, Listing Department,

Dalal Street, National Stock Exchange of India Ltd., Mumbai - 400 001 Exchange Plaza, Bandra Kurla Complex,

Ref: Company Scrip Code: 532834 Bandra (East), Mumbai- 400051

Ref: Symbol: CAMLINFINE | | Series: EQ

Sub: Outcome of the meeting of the Securities Issue and Allotment Committee of the Board of Directors of Camlin Fine Sciences Limited (the "Company") held on January 31, 2025 -Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

Dear Sir/Madam,

This is with reference to our intimations dated September 10, 2024, November 22, 2024, January 2, 2025 and January 9, 2025 in relation to the raising of funds by way of an issue of equity shares through rights issue ("Rights Issue"), and approving various terms of the Rights Issue and the Letter of Offer for issue of 2,04,26,244 fully paid-up equity shares of the Company of face value of ₹ 1 each ("Equity Shares").

In relation to the aforesaid Rights Issue and pursuant to the finalization of the Basis of Allotment of the Rights Issue in consultation with the Lead Managers, the Registrar to the Issue and BSE Limited, the Designated Stock Exchange, the Securities Issue and Allotment Committee (the "Committee") of the Company at its meeting held today i.e. on Friday, January 31, 2025, inter-alia, considered and approved the allotment of 2,04,25,805 fully paid-up Equity Shares at an issue price of ₹ 110 per Rights Equity Share (including a premium of ₹ 109 per Rights Equity Share) to eligible equity shareholders or applicants (renouncee), as the case may be pursuant to the Rights Issue. Further, 439 Rights Equity Shares have been kept in abeyance pending regulatory/other clearances, as may be applicable.

Accordingly, the paid-up equity share capital of the Company has increased from ₹ 16,74,95,207 to ₹ 18,79,21,012 by addition of 2,04,25,805 equity shares.

The said fully paid-up Equity Shares allotted to eligible equity shareholders or applicants (renouncee), as the case may be, shall rank pari-passu in all respect with the existing fully paid-up Equity Shares of the Company.

This is in accordance with Regulation 30 read with Schedule III of the SEBI Listing Regulations.

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098. CIN: L74100MH1993PLC075361












The meeting of the Committee commenced at 02:30 p.m. and concluded at 03:15 p.m.

We request you to take the aforesaid on records.

Thanking you, Yours faithfully, **For Camlin Fine Sciences Limited** 

**Rahul Sawale** Company Secretary & V. P. Legal



Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098. CIN: L74100MH1993PLC075361







